The platform's patient-focused outreach is beneficial in navigating the complexities of evolving eligibility criteria for ...

Pfizer has terminated a Phase II study of its CD47 immune checkpoint inhibitor, maplirpacept, due to low recruitment. In an ...

Smith joins Trially at a pivotal moment. As clinical research sites face mounting enrollment pressure and shrinking pipelines, Trially has emerged as a category-defining technology. In a landscape ...

The ophthalmic drug development industry is undergoing significant transformation, marked by unprecedented advancements in ...

Create vital connections that move patients from the shadows of isolation into the heart of clinical innovation ...

For rare disease trials or studies with strict eligibility criteria, they often prolong recruitment timelines, raise costs, and limit patient diversity, hindering access to developing therapies.